Results 81 to 90 of about 2,385 (197)

Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction

Platelets, 2020
Cangrelor is an intravenously administered P2Y12 receptor antagonist, which has been approved for adult patients undergoing percutaneous coronary intervention and, due to its unique pharmacokinetics, it allows effective and controllable peri-procedural ...
Domenico Sirico, Nuccia Morici, Francesco Soriano, Stefano Maria Marianeschi, Giovanna Pedrazzini, Sergio Leonardi, Gabriele Vignati   +6 more
doaj   +1 more source

Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y 12 receptors in vitro [PDF]

, 2015
Cangrelor is a rapid-acting, direct-binding, and reversible P2Y12 antagonist which has been studied for use during percutaneous coronary intervention (PCI) in patients with or without pretreatment with an oral P2Y12 antagonist.
Storey, R.F., Jakubowski, J.A., Judge, H.M., Buckland, R.   +3 more
core   +1 more source

Spanish Registry of Pressure‐Controlled Intermittent Coronary Sinus Occlusion (PiCSO) Balloon: Initial Experience and Short‐Term Clinical Outcomes

Journal of Interventional Cardiology, Volume 2025, Issue 1, 2025.
Objectives: The mortality of ST elevation myocardial infarction (STEMI) has plateaued in the last decade, with a 30‐day mortality of 3%‐4%. Previous studies in patients with anterior STEMI treated by primary angioplasty and assisted with the pressure‐controlled intermittent coronary sinus occlusion (PiCSO) system have shown a modest but significant ...
Erick Dante Martínez Maldonado, Victor Alfonso Jiménez Díaz, Guillermo Bastos Fernández, Pablo Vidal Calés, Salvatore Brugaletta, Pablo Juan Salvadores, Andrés Íñiguez Romo, Stefano Rigattieri   +7 more
wiley   +1 more source

High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction [PDF]

, 2020
Transition from cangrelor to oral P2Y12 inhibitors after PCI carries the risk of platelet function recovery and acute stent thrombosis. Whether the recommended transition regimen is appropriate for hypothermic cardiac arrest survivors is unknown.
Anne Merrelaar, Nina Buchtele, Alexander O. Spiel, Georg Gelbenegger, Irene Lang, Hans Domanovits, Michael Schwameis, Roberta Laggner, Harald Herkner, Christian Schörgenhofer, Bernd Jilma   +10 more
core   +1 more source

Cangrelor in Patients with Percutaneous Coronary Intervention (PCI) After out-of-Hospital Cardiac Arrest (OHCA): A Propensity Score Matchig Analysis

Epidemiology, Biostatistics and Public Health
Introduction: Propensity Score Matching (PSM) is used in observational studies to measure the effect of a treatment by removing the bias of confounders, as randomisation is not possible.
Sara Bendotti , Roberto Primi , Luca Raone , Marco Ferlini , Alessia Currao , Andrea Bongiorno , Cristian Fava , Daniele Ghiraldin , Cinzia Dossena , Andrea Baldo , Diego Maffeo , Vilma Kajana , Silvia Affinito , Leila Ulmanova , Enrico Baldi , Simone Savastano   +15 more
doaj   +1 more source

Blood–brain barrier profile pretreatment is associated with hemorrhagic transformation after endovascular reperfusion

Annals of Clinical and Translational Neurology, Volume 11, Issue 12, Page 3292-3299, December 2024.
Abstract Background While advances in endovascular thrombectomy (EVT) have led to high reperfusion rates, most patients treated with EVT do not avoid disability. Post‐reperfusion hemorrhagic transformation (HT) is a potential target for improving outcomes.
Richard Leigh, Pierre Seners, Vanessa Rousseau, Soren Christensen, Jean‐François Albucher, Amel Drif, Christophe Cognard, Adrien Guenego, Alain Viguier, Agnes Sommet, Nicolas Raposo, Lionel Calviere, Anne‐Christine Januel, Michael Mlynash, Fabrice Bonneville, Brice Gaudilliere, Claire Thalamas, Igor Sibon, Thomas Tourdias, Mikael Mazighi, Jeremy J Heit, Benjamin Maier, Gregory W. Albers, Jean‐Marc Olivot, on behalf of the FRAME Investigators   +24 more
wiley   +1 more source

Hemin‐induced platelet activation is regulated by the ACKR3 chemokine surface receptor and has implications for passivation of vulnerable atherosclerotic plaques

The FEBS Journal, Volume 291, Issue 24, Page 5420-5434, December 2024.
Intraplaque hemorrhages (IPH) result in hemolysis and liberation of iron‐containing heme and its oxidized metabolite, hemin. Hemin activates platelets and has strong prothrombotic activity. Here, we show that agonism of the atypical chemokine receptor 3 (ACKR3) inhibits hemin‐induced platelet activation.
Zoi Laspa, Valerie Dicenta‐Baunach, David Schaale, Manuel Sigle, Ravi Hochuli, Tatsiana Castor, Alp Bayrak, Tobias Harm, Karin Anne Lydia Müller, Thanigaimalai Pillaiyar, Stefan Laufer, Anne‐Katrin Rohlfing, Meinrad Paul Gawaz   +12 more
wiley   +1 more source

Practical considerations for cangrelor use in patients with acute coronary syndromes [PDF]

, 2017
Cangrelor, the first and currently only available intravenous P2Y12 receptor antagonist, has been approved and is now being used in patients with coronary artery disease requiring percutaneous coronary intervention.
Deepak L Bhatt, Sergio Leonardi
core   +1 more source

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use

Therapeutic Advances in Cardiovascular Disease, 2019
Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or stable coronary artery disease undergoing percutaneous coronary intervention (PCI).
Davide Capodanno, Rocco P. Milluzzo, Dominick J. Angiolillo   +2 more
doaj   +1 more source

P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease

JACC: Basic to Translational Science, 2017
Shunt thrombosis remains a major cause of morbidity and mortality, especially during the initial palliation for single-ventricle physiology. The authors present evidence that the P2Y12 inhibitor cangrelor may fill a therapeutic void in thromboprophylaxis.
Elisabeth A. Kaza, MD, Matthew C. Egalka, MD, Hairu Zhou, MS, Jianchun Chen, PhD, Denise Evans, MSHS, Jayne Prats, PhD, Ruizhi Li, PhD, Scott L. Diamond, PhD, Julie A. Vincent, MD, Emile A. Bacha, MD, Thomas G. Diacovo, MD   +10 more
doaj   +1 more source